FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Phase 2

Recruiting

Conditions: Myeloid Neoplasm
Acute Myeloid Leukemia

Interventions: Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Cladribine
Other: Questionnaire Administration
Drug: Cytarabine
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Mitoxantrone
Other: Quality-of-Life Assessment

First Posted Date: 2019-12-12

Last Posted Date: 2024-03-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04195945

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

First Posted Date: 2019-12-12

Last Posted Date: 2024-08-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04195633

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers

Phase 1

Completed

Conditions: Tobacco Use Disorder

Interventions: Behavioral: Computer-Assisted Smoking Cessation Intervention
Other: Text Message
Other: Handout
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Other: Survey Administration

First Posted Date: 2019-12-11

Last Posted Date: 2020-10-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT04194918

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Optical Coherence Tomography
Procedure: Spirometry
Other: Survey Administration
Other: Digital Photography
Other: Quality-of-Life Assessment
Other: Medical Chart Review

First Posted Date: 2019-12-06

Last Posted Date: 2024-04-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 200

Registration Number: NCT04188912

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States

and more 4 locations

Glasdegib for Chronic Graft-Versus-Host Disease

Phase 1

Terminated

Conditions: Chronic Graft Versus Host Disease
Fasciitis

Interventions: Drug: Glasdegib

First Posted Date: 2019-10-01

Last Posted Date: 2024-10-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04111497

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Phase 1

Suspended

Conditions: Non-Malignant Neoplasm

Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Lapine T-Lymphocyte Immune Globulin
Radiation: Total-Body Irradiation
Procedure: Hematopoietic Cell Transplantation
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2019-09-10

Last Posted Date: 2024-12-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04083183

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Phase 2

Terminated

Conditions: Acute Megakaryoblastic Leukemia
Acute Myeloid Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection
Acute Erythroid Leukemia
Myelodysplastic Syndrome With Excess Blasts
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Drug: Thiotepa
Procedure: Umbilical Cord Blood Transplantation
Biological: Dilanubicel

First Posted Date: 2019-09-10

Last Posted Date: 2024-06-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04083170

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Cleveland Cord Blood Center, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 2 locations

Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

Not Applicable

Conditions: Colorectal Carcinoma
Lung Carcinoma
Lymphoma
Prostate Carcinoma
Breast Carcinoma

Interventions: Other: Survivorship Care Plan
Other: Questionnaire Administration
Other: Educational Intervention

First Posted Date: 2019-09-09

Last Posted Date: 2024-07-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 200

Registration Number: NCT04081779

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors

Not Applicable

Terminated

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Behavioral: Health Education
Other: Physical Activity
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-09-09

Last Posted Date: 2023-07-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04081298

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants

Not Applicable

Completed

Conditions: Healthy Subject

Interventions: Dietary Supplement: Dietary Intervention
Procedure: Dual X-ray Absorptiometry
Other: Questionnaire Administration

First Posted Date: 2019-08-20

Last Posted Date: 2021-01-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT04062955

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy